Remove Bioinformatics Remove Genetics Remove Trials
article thumbnail

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials. Optimal methods for bioinformatic analysis are still needed. percent show less reliability).

article thumbnail

How Will Ultima Genomics and Genome Insight Make WGS Affordable?

XTalks

Biotech company Ultima Genomics has joined forces with Genome Insight, a bioinformatics-based biomedicine company, to overcome the caveat of cost and quality in WGS. Genome sequencing requires a powerful sequencer to decode the genetic makeup and an equally powerful analysis platform to make sense of the data generated.

Genome 97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

Well, Kim believes that “by leveraging the power of genetics and functional genomics, coupled with a ‘human-first’ mindset, innovative analytics, and scalable compute power” there is “the ability to take a fundamentally different approach to drug development”. It also bodes well for improving clinical trial success rates.

article thumbnail

The future of genomic medicine: can it fulfil its promises?

pharmaphorum

Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. While it is a very rare form of epilepsy, it is such a cheap and harmless medication that it is often used as a first-line therapy for infants in intensive care who have no genetic diagnosis.

Genome 119
article thumbnail

Top 10 Fastest Growing Biotech Companies in 2023

XTalks

The company’s sustained investment in R&D has led to a rapid expansion of its pipeline in 2023, with notable milestones such as four infectious disease vaccines in Phase III trials, including the recently submitted respiratory syncytial virus (RSV) vaccine for regulatory approval.

Genetics 111
article thumbnail

LabCorp Backs Resolution Bioscience’s Liquid Biopsy Test for NSCLC

XTalks

Related: Liquid Biopsies Help Match Cancer Patients to Phase I Trials. The test is based on the detection of actionable genes – genes with known driver mutations that can be targeted by an approved therapy (or investigational therapies in clinical trials).

Gene 105
article thumbnail

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

STAT News

Unlike most people who receive medications yet to be cleared by the Food and Drug Administration, none of these patients is getting the vaccines as part of a clinical trial. Thirteen patients are waiting for their vaccine to be made. Typically, those patients pay nothing, in contrast to the foundation initiative.